Nitoman (Tetrabenazine)

Tetrabenazine, the active ingredient in Nitoman, is a VMAT2 inhibitor presented as an oral tablet for oral use. It is employed to manage involuntary movements associated with Huntington’s disease and to treat tardive dyskinesia in adult patients. By inhibiting vesicular monoamine transporter 2, it lowers central dopamine levels, helping to control chorea and dyskinetic movements.

GNH USA supplies Nitoman as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company ensures rigorous quality assurance and regulatory compliance for all shipments.

Tetrabenazine is indicated for movement‑disorder conditions that involve excessive dopaminergic activity.

Huntington’s disease: reduces chorea and other involuntary movements, improving functional ability. Tardive dyskinesia: alleviates abnormal facial and limb movements caused by long‑term antipsychotic use.

Tetrabenazine may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Drowsiness: feeling of sleepiness or reduced alertness. - Nausea: upset stomach and urge to vomit. - Fatigue: general lack of energy. - Insomnia: difficulty falling or staying asleep.

Serious or Rare Side Effects: - Suicidal thoughts: emergence of depression or suicidal ideation. - Severe depression: marked mood changes requiring immediate medical attention. - QT prolongation: abnormal heart rhythm that can lead to cardiac events.

When prescribing tetrabenazine, clinicians should observe several safety considerations to minimize risk.

- Depression monitoring: regularly assess patients for signs of depression or suicidal behavior. - Cardiac evaluation: avoid use in patients with known QT prolongation or significant cardiac disease. - Hepatic function: adjust dose or avoid in severe liver impairment. - Pregnancy and lactation: use is not recommended as safety data are lacking; consider risks versus benefits. - Elderly caution: start at low dose and titrate slowly due to increased sensitivity. - Store at ambient temperature: keep tablets in original container, protect from moisture and light.

Tetrabenazine can interact with other medicines, influencing its efficacy or safety.

Major Interactions (Avoid): - MAO inhibitors: risk of hypertensive crisis and serotonin syndrome. - CNS depressants: additive sedation and respiratory depression. - Antipsychotics that increase dopamine: may reduce therapeutic effect.

Moderate Interactions (Monitor Closely): - CYP2D6 inhibitors (e.g., fluoxetine, paroxetine): increase tetrabenazine levels, may require dose adjustment. - QT‑prolonging agents (e.g., quinidine, sotalol): may enhance cardiac risk. - Antihypertensives: may potentiate blood pressure lowering.